Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding

• Caroti Caroti,
• Becattini Becattini,
• Carrier Carrier,
• Cohen Cohen,
• Ekbom Ekbom,
• Khorana Khorana,
• Lee Lee,
• Brescia Brescia,
• Abdelgawwad Abdelgawwad,
• Psaroudakis Psaroudakis,
• Rivera Rivera,
• Schaefer Schaefer,
• Brobert Brobert,
• Coleman Coleman

Affiliations

Caroti Caroti

Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut, United States

Becattini Becattini

Department of Internal and Emergency Medicine – Stroke Unit, University of Perugia, Perugia, Italy

Carrier Carrier

Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Canada

Cohen Cohen

Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom

Ekbom Ekbom

Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden

Khorana Khorana

Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lee Lee

Department of Medicine, University of British Columbia and BC Cancer, Vancouver, Canada

Brescia Brescia

Freshtech IT, LLC, East Hartford, Connecticut, United States

Abdelgawwad Abdelgawwad

Pharmacoepidemiology Group, Bayer AG, Berlin, Germany

Psaroudakis Psaroudakis

Pharmacoepidemiology Group, Bayer AG, Berlin, Germany

Rivera Rivera

Pharmacoepidemiology Group, Bayer AG, Berlin, Germany

Schaefer Schaefer

Pharmacoepidemiology Group, Bayer AG, Berlin, Germany

Brobert Brobert

Pharmacoepidemiology Group, Bayer AG, Berlin, Germany

Coleman Coleman

ORCiD

Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut, United States